Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use XATMEP® safely and effectively. See full prescribing information for XATMEP. XATMEP (methotrexate) oral solution Initial U.S. Approval: 1953
Medication labelWhy this: Advisory · dailymed-prescription
XATMEP is indicated for the treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a multi-phase, combination chemotherapy maintenance regimen. XATMEP is indicated in the management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs).
- generic_name
- methotrexate
- product_names
- Methotrexate
- ndc
- 52652-2001, 52652-2001-1, 52652-2001-6
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en